New real-world evidence on the MSDA Test published in The Multiple Sclerosis Journal – ET&C. Read the press release.
New real-world evidence on the MSDA Test published in The Multiple Sclerosis Journal – ET&C. Read the press release.
Octave is committed to providing cutting edge tools to support the monitoring and management of neurological diseases.
Inflammatory and neurodegenerative serum protein biomarkers increase sensitivity to detect clinical and radiographic disease activity in multiple sclerosis. Read manuscript here.
AUTHORS
Chitnis, T., Qureshi, F., Gehman, V. M., Becich, M., Bove, R., et al. (2024).
Analytical validation of a multi-protein serum-based assay for disease activity assessments in multiple sclerosis. Read manuscript here.
AUTHORS
Qureshi, F., Hu, W., Loh, L., Patel, H., DeGuzman, M., et al. (2023).
Clinical validation of the 18-protein Octave® MSDA Test. Read manuscript here.
AUTHORS
Chitnis, T., Foley, J., Ionete, C., El Ayoubi, N. K., Saxena, S., et al. (2023).
